Table 3.
Susceptibility pattern of bloodstream bacteria
| Antibiotics | Gram-positive bacteria (n =64)
|
||||
|---|---|---|---|---|---|
|
Staphylococcus epidermidis (n=26) n (% susceptible) |
Staphylococcus haemolyticus (n=7) n (% susceptible) |
Staphylococcus hominis (n=9) n (% susceptible) |
Other G+ve bacteria (n=22) n (% susceptible) |
||
| Clindamycin | 17 (53) | 6 (85) | 5 (60) | 8 (88) | |
| Oxacillin | 23 (8) | 7 (0.00) | 9 (22) | 8 (88) | |
| Erythromycin | 26 (100) | 7 (12) | 7 (28) | 9 (78) | |
| Gentamicin | 26 (73) | 7 (37) | 9 (77) | 15 (87) | |
| Linezolid | 15 (100) | 4 (100) | 7 (100) | 5 (100) | |
| Vancomycin | 26 (96) | 7 (100) | 9 (100) | 18 (94) | |
| Teicoplanin | 20 (95) | 7 (87) | 8 (100) | 9 (100) | |
| Streptogramins | 14 (100) | 4 (100) | 6 (100) | 3 (100) | |
| Cefazolin | 16 (0.00) | 7 (0.00) | 4 (25) | 6 (33) | |
| TMX-SMX | 23 (16) | 7 (20) | 8 (25) | 7 (57) | |
| Antibiotic |
Gram-negative isolates (n =52)
|
||||
|
Pseudomonas aeruginosa (n=10) n (% susceptible) |
Acinetobacter baumannii (n=6) n (% susceptible) |
Escherichia coli (n=7) n (% susceptible) |
Klebsiella pneumonia (n=14) n (% susceptible) |
Other G-ve bacteria (n=15) n (% susceptible) |
|
|
| |||||
| Cefepime | 7 (100) | 5 (100) | 7 (33) | 12 (83) | 13 (77) |
| Gentamicin | 7 (100) | 6 (100) | 7 (55) | 12 (75) | 11 (64) |
| Piperacillin/tazobactam | 8 (100) | 5 (100) | 7 (100) | 9 (78) | 12 (92) |
| Amikacin | 8 (100) | 6 (100) | 7 (100) | 13 (100) | 14 (86) |
| Ceftriaxone | ND | 3 (33) | 7 (29) | 10 (80) | 9 (44) |
| Ciprofloxacin | 7 (100) | 6 (100) | 7 (78) | 11 (82) | 12 (83) |
| Meropenem | 8 (100) | 5 (100) | 7 (100) | 12 (100) | 13 (69) |
| Imipenem | 4 (100) | 2 (100) | 7 (100) | 10 (100) | 14 (79) |
| TMX-SMX | ND | 6 (100) | 7 (11) | 12 (42) | 11 (82) |
| Ceftazidime | 7 (100) | 6 (100) | 8 (50) | 13 (77) | 13 (77) |
Abbreviations: ND, not done; TMX-SMX, trimethoprim sulfamethoxazole.